Tailoring neoadjuvant chemotherapy for a pregnant patient diagnosed with IB2 squamous cervical carcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43927661" target="_blank" >RIV/00064173:_____/24:43927661 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/24:43927661

Výsledek na webu

<a href="https://doi.org/10.1016/j.gore.2024.101532" target="_blank" >https://doi.org/10.1016/j.gore.2024.101532</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.gore.2024.101532" target="_blank" >10.1016/j.gore.2024.101532</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Tailoring neoadjuvant chemotherapy for a pregnant patient diagnosed with IB2 squamous cervical carcinoma

Popis výsledku v původním jazyce

The incidence of cancer during pregnancy is steadily rising because of the postponement of plans for childbearing. One of the most common cancers diagnosed during pregnancy is cervical cancer. Diagnosis of most cases usually occurs in the early stages, but there are still cases of tumors staged IB2 and higher. In these cases, the treatment strategy entails administration of neoadjuvant chemotherapy. However, a universally recognized standardized regimen for neoadjuvant chemotherapy treatment of cervical cancer during pregnancy has yet to be established. The chemotherapy agents used during treatment are known for their fetal adverse effects. The aim of the therapy is to attain full-term pregnancy while minimizing fetal toxicity and decreasing tumor size. In this case report, we present a first-time sequential chemotherapy administration to minimize the cumulative toxicity of individual regimens and demonstrate the benefits for the patient and fetus.

Název v anglickém jazyce

Tailoring neoadjuvant chemotherapy for a pregnant patient diagnosed with IB2 squamous cervical carcinoma

Popis výsledku anglicky

The incidence of cancer during pregnancy is steadily rising because of the postponement of plans for childbearing. One of the most common cancers diagnosed during pregnancy is cervical cancer. Diagnosis of most cases usually occurs in the early stages, but there are still cases of tumors staged IB2 and higher. In these cases, the treatment strategy entails administration of neoadjuvant chemotherapy. However, a universally recognized standardized regimen for neoadjuvant chemotherapy treatment of cervical cancer during pregnancy has yet to be established. The chemotherapy agents used during treatment are known for their fetal adverse effects. The aim of the therapy is to attain full-term pregnancy while minimizing fetal toxicity and decreasing tumor size. In this case report, we present a first-time sequential chemotherapy administration to minimize the cumulative toxicity of individual regimens and demonstrate the benefits for the patient and fetus.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30214 - Obstetrics and gynaecology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Gynecologic Oncology Reports

ISSN

2352-5789

e-ISSN

2352-5789

Svazek periodika

56

Číslo periodika v rámci svazku

December

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

5

Strana od-do

101532

Kód UT WoS článku

001340004500001

EID výsledku v databázi Scopus

2-s2.0-85206684385